Research & Literature

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.

Bruno OD, Juárez-Allen L, Christiansen SB, et al.

International journal of endocrinology 2015; (2015()):587893 doi:10.1155/2015/587893.

Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Miermeister CP, Petersenn S, Buchfelder M, et al.

Acta neuropathologica communications 2015; (3()):50 doi:10.1186/s40478-015-0229-8.

Pituitary Apoplexy.

Briet C, Salenave S, Bonneville JF, et al.

Endocrine reviews 2015; (36(6)):622-45 doi:10.1210/er.2015-1042.

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

Losa M, Bogazzi F, Cannavo S, et al.

Journal of neuro-oncology 2016; (126(3)):519-25 doi:10.1007/s11060-015-1991-y.

Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.

Alexandraki KI, Grossman AB

Drugs 2016; (76(4)):447-58 doi:10.1007/s40265-016-0539-6.

Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions.

Seltzer J, Carmichael JD, Commins D, et al.

World neurosurgery 2016; (91()):676.e23-8.

Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.

Lengacher CA, Reich RR, Paterson CL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(24)):2827-34 doi:10.1200/JCO.2015.65.7874.

How effective is temozolomide for treating pituitary tumours and when should it be used?

Halevy C, Whitelaw BC

Pituitary 2017; (20(2)):261-266 doi:10.1007/s11102-016-0745-y.

Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease.

Joehlin-Price AS, Hardesty DA, Arnold CA, et al.

Diagnostic pathology 2017; (12(1)):34 doi:10.1186/s13000-017-0624-5.

Presenting Symptoms of Pituitary Apoplexy.

Pyrgelis ES, Mavridis I, Meliou M

Journal of neurological surgery. Part A, Central European neurosurgery 2018; (79(1)):52-59 doi:10.1055/s-0037-1599051.

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

Raverot G, Burman P, McCormack A, et al.

European journal of endocrinology 2018; (178(1)):G1-G24.

Ectopic ACTH syndrome complicated by multiple opportunistic infections treated with percutaneous ablation of the adrenal glands.

Chan C, Roberts JM

BMJ case reports 2017; (2017()) doi:10.1136/bcr-2017-221580.

Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Yoo F, Kuan EC, Heaney AP, et al.

Pituitary 2018; (21(3)):290-301 doi:10.1007/s11102-018-0872-8.

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Lin AL, Jonsson P, Tabar V, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(10)):3925-3930 doi:10.1210/jc.2018-01347.

Clinical and biochemical characteristics of patients presenting with pituitary apoplexy.

Abbara A, Clarke S, Eng PC, et al.

Endocrine connections 2018; (7(10)):1058-1066 doi:10.1530/EC-18-0255.

An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Alshaikh OM, Asa SL, Mete O, Ezzat S

Endocrine pathology 2019; (30(2)):118-127 doi:10.1007/s12022-019-9568-5.

Double pituitary adenomas in a large surgical series.

Zieliński G, Sajjad EA, Maksymowicz M, et al.

Pituitary 2019; (22(6)):620-632 doi:10.1007/s11102-019-00996-2.

Multimodal therapy in aggressive pituitary tumors.

Iglesias P, Magallón R, Mitjavila M, et al.

Endocrinologia, diabetes y nutricion 2020; (67(7)):469-485 doi:10.1016/j.endinu.2019.08.004.

Pituitary carcinoma: Two case reports and review of literature.

Xu L, Khaddour K, Chen J, et al.

World journal of clinical oncology 2020; (11(2)):91-102 doi:10.5306/wjco.v11.i2.91.

A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.

Carey RM, Kuan EC, Workman AD, et al.

Journal of neurological surgery. Part B, Skull base 2020; (81(2)):180-186 doi:10.1055/s-0039-1683435.

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.

Majd N, Waguespack SG, Janku F, et al.

Journal for immunotherapy of cancer 2020; (8(2)) doi:10.1136/jitc-2020-001532.

Non-functional recurrent pituitary adenoma with intracranial metastasis-Pituitary carcinoma: A case report and review of the literature.

Demir MK, Yapıcıer O, Oral A, et al.

Neuro-Chirurgie 2022; (68(1)):106-112 doi:10.1016/j.neuchi.2021.02.006.

Pituitary adenoma…nomen omen?

Giustina A

Endocrine 2021; (74(1)):1-4 doi:10.1007/s12020-021-02785-z.

Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Yamamoto M, Nakao T, Ogawa W, Fukuoka H

Frontiers in endocrinology 2021; (12()):650791 doi:10.3389/fendo.2021.650791.

Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.

Ng S, Messerer M, Engelhardt J, et al.

Acta neurochirurgica 2021; (163(11)):3131-3142 doi:10.1007/s00701-021-04953-6.

Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.

Lin AL, Tabar V, Young RJ, et al.

Journal of the Endocrine Society 2021; (5(10)):bvab133 doi:10.1210/jendso/bvab133.

Growth hormone secreting pituitary carcinomas: Case report and review of literature.

Vekaria S, Chen F, Zan E, et al.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2021; (60-61()):101430 doi:10.1016/j.ghir.2021.101430.

A Rare Case of Pituitary Carcinoma With Bone Metastases: 68Ga-DOTATATE PET/CT Findings.

Filizoglu N, Ozguven S

Clinical nuclear medicine 2022; (47(3)):e298-e299 doi:10.1097/RLU.0000000000004029.

Overview of the 2022 WHO Classification of Pituitary Tumors.

Asa SL, Mete O, Perry A, Osamura RY

Endocrine pathology 2022; (33(1)):6-26 doi:10.1007/s12022-022-09703-7.

Corticotroph pituitary carcinoma with skeletal metastases masquerading as ectopic ACTH syndrome: a long and winding road to diagnosis.

Van Mieghem E, Intan-Goey V, Buffet W, et al.

Endocrinology, diabetes & metabolism case reports 2022; (2022()).

Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.

Raghu ALB, Everson MC, Helal A, et al.

Journal of neurological surgery. Part B, Skull base 2022; (83(Suppl 2)):e253-e259 doi:10.1055/s-0041-1725024.

Rapidly progressive ACTH-dependent Cushing's disease masquerading as ectopic ACTH-producing Cushing's syndrome: illustrative case.

Yu S, Karsy M, Miller J, et al.

Journal of neurosurgery. Case lessons 2021; (2(1)):CASE21151 doi:10.3171/CASE21151.

Apoplexy in sellar metastasis from papillary thyroid cancer: A case report and literature review.

Hirayama M, Ishida A, Inoshita N, et al.

Surgical neurology international 2022; (13()):253 doi:10.25259/SNI_131_2022.

Treatment of Prolactinoma.

Inder WJ, Jang C

Medicina (Kaunas, Lithuania) 2022; (58(8)) doi:10.3390/medicina58081095.

Temozolomide in aggressive pituitary tumours and pituitary carcinomas.

McCormack A

Best practice & research. Clinical endocrinology & metabolism 2022; (36(6)):101713 doi:10.1016/j.beem.2022.101713.

Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.

Gamboa NT, Wilkerson C, Kundu B, et al.

Journal of neurosurgery. Case lessons 2023; (5(3)).

Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review.

Raymond P, Raverot G, Ilie MD

Endocrine-related cancer 2023; (30(5)).

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.

Marques P

Cancers 2023; (15(10)) doi:10.3390/cancers15102710.

Pituitary carcinoma: reclassification and implications in the NET schema.

Asa SL, Ezzat S

Endocrine oncology (Bristol, England) 2022; (2(1)):R14-R23 doi:10.1530/EO-22-0041.

Metastatic pituitary tumors: an institutional case series.

Yearley AG, Chalif EJ, Gupta S, et al.

Pituitary 2023; (26(5)):561-572 doi:10.1007/s11102-023-01341-4.

Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.

Ho KKY, Kaiser UB, Chanson P, et al.

Nature reviews. Endocrinology 2023; (19(11)):671-678 doi:10.1038/s41574-023-00883-8.

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.

Lamas C, Cámara R, Fajardo C, et al.

Frontiers in endocrinology 2023; (14()):1204206 doi:10.3389/fendo.2023.1204206.

Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.

Iglesias P

Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010116.

Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.

DE Alcubierre D, Carretti AL, Ducray F, et al.

Minerva endocrinology 2024; (49(3)):321-334 doi:10.23736/S2724-6507.23.04058-7.

Diagnosis and management of secondary adrenal crisis.

Martel-Duguech L, Poirier J, Bourdeau I, Lacroix A

Reviews in endocrine & metabolic disorders 2024; (25(3)):619-637 doi:10.1007/s11154-024-09877-x.

How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?

Constantinescu SM, Duprez T, Bonneville JF, Maiter D

Annales d'endocrinologie 2024; (85(4)):300-307 doi:10.1016/j.ando.2024.03.004.

How to standardize the diagnostic approach to pituitary neuroendocrine tumors.

Asioli S, Guaraldi F, Zoli M, et al.

Minerva endocrinology 2024; (49(3)):283-292 doi:10.23736/S2724-6507.24.04079-X.

Pituitary Apoplexy: An Updated Review.

Iglesias P

Journal of clinical medicine 2024; (13(9)) doi:10.3390/jcm13092508.

How do mindfulness-based interventions promote coping and self-efficacy in patients with cancer: A systematic review of qualitative and quantitative data.

Heinen JM, Laing EM, Schäffeler N, et al.

Psycho-oncology 2024; (33(5)):e6350 doi:10.1002/pon.6350.

Social isolation, coping efficacy, and social well-being over time in patients with lung cancer.

Dunsmore VJ, Neupert SD

Journal of behavioral medicine 2024; (47(5)):927-934 doi:10.1007/s10865-024-00508-z.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

The role of intervention timing and treatment modality in visual recovery following pituitary apoplexy: a systematic review and meta-analysis.

Brown NJ, Patel S, Gendreau J, Abraham ME

Journal of neuro-oncology 2024; (170(3)):469-482 doi:10.1007/s11060-024-04717-z.

Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors.

Lin AL, Rudneva V, Newton A, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(11)):3066-3073 doi:10.1210/clinem/dgaf178.

Comprehensive Classification of Surgically Resected Pituitary Neuroendocrine Tumors: Updates From a Single-Institution Experience Based on the WHO 5th Edition.

Kim H, Kim EE, Kim YH, et al.

Journal of Korean medical science 2025; (40(16)):e56 doi:10.3346/jkms.2025.40.e56.

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

Raverot G, Burman P, Abreu AP, et al.

European journal of endocrinology 2025; (192(6)):R45-R78 doi:10.1093/ejendo/lvaf100.

Imaging and clinical course of metastatic pituitary neuroendocrine tumors (PitNET): A single center case series.

Dagher SA, Alizada S, Al Qudah H, et al.

The neuroradiology journal 2026; (39(2)):222-230 doi:10.1177/19714009251356278.

Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.

Calvanese F, Jannelli G, Feuvret L, et al.

Neuro-oncology advances 2025; (7(Suppl 1)):i17-i28 doi:10.1093/noajnl/vdae114.

Update in the Management of ACTH-Secreting Gastroenteropancreatic and Thoracic Neuroendocrine Neoplasms.

Tsoli M, Bel-Ange A, Atlan K, et al.

Current treatment options in oncology 2025; (26(11)):1010-1022 doi:10.1007/s11864-025-01354-0.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor.

Wolf KI, Lu Z, Hesseltine EA, et al.

Endocrine oncology (Bristol, England) 2025; (5(1)):e250073 doi:10.1530/EO-25-0073.

"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

Derry-Vick H, Prigerson HG, Hahne J, et al.

Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

Hypokalemic metabolic alkalosis as a clinical clue to ectopic ACTH syndrome: two cases of neuroendocrine carcinoma.

Torun C, Eken E, Cakır B, Uzunlulu M

Endocrine regulations 2025; (59(1)):265-270 doi:10.2478/enr-2025-0031.

Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome.

Htut Z, Mundhra A, Lazarus K, et al.

The Journal of clinical endocrinology and metabolism 2026; (111(6)):e1477-e1484 doi:10.1210/clinem/dgag014.

Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.

Haberbosch L, MacFarlane J, Gillett D, et al.

The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S89-S106 doi:10.1210/clinem/dgag179.

Adrenocorticotropin-secreting pituitary macroadenomas: expanding the clinical spectrum.

Iyer C, Havenga N, Roytowski D, et al.

JCEM case reports 2026; (4(7)):luag127 doi:10.1210/jcemcr/luag127.

Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).

Lin S, Chen Z, Ji L, et al.

Chinese neurosurgical journal 2026; (12(1)).

Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series.

Faraj CA, Tran M, Ferguson SD, et al.

Cancers 2026; (18(13)) doi:10.3390/cancers18132064.

Postoperative Management After Transsphenoidal Resection of Pituitary Tumors.

Nadel JL, Abdelgadir J, Budohoski KP, et al.

Neurology India 2026; (74(4)):653-656 doi:10.4103/neurol-india.Neurol-India-D-25-00992.